(Sharecast News) - Faron Pharmaceuticals, a clinical-stage biopharmaceutical company specialising in immunotherapies for cancer and inflammatory diseases, announced the filing of a new patent application for the use of soluble Clever-1 in targeting T-cell inactivation on Monday, with potential applications in treating autoimmune diseases and inflammatory disorders.
The AIM-traded firm said...

Email this article to a friend

or share it with one of these popular networks:

• DIGG
• FACEBOOK
• STUMBLEUPON
• MIXX
• YAHOO BUZZ
• DELICIOUS
• REDDIT
• NEWSVINE